Zentalis Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Zentalis Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 89% of its market value (net cash). Higher than 87% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+89%Cash, after subtracting all debt, equals 89% of its market value (net cash).
Higher than 87% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Zentalis Pharmaceuticals, Inc. made a loss over the last year. Zentalis Pharmaceuticals, Inc. owes $0.33 for every $1 it owns. Zentalis Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossZentalis Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.51The share price is 1.51 times Zentalis Pharmaceuticals, Inc.'s book value per share, lower than 66% of Healthcare companies in United States.
Market cap
$217 MThe total market value of all of Zentalis Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$144 MWhat Zentalis Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.46Net worth divided by the number of shares. The share price of $2.21 is 1.5 times this, which is the P/B above.
Return on equity (ROE)
-66.8%Zentalis Pharmaceuticals, Inc. lost 66.8% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
Owes vs Owns
0.33×Zentalis Pharmaceuticals, Inc. owes $0.33 for every $1 it owns (low), lower than 57% of Healthcare companies in United States.
Dividend yield
NoneZentalis Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossZentalis Pharmaceuticals, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashZentalis Pharmaceuticals, Inc. held $210 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Zentalis Pharmaceuticals, Inc.: $217 M ÷ $144 M (30 Jun 2026) = 1.5.
What is Zentalis Pharmaceuticals, Inc.'s return on equity?
Zentalis Pharmaceuticals, Inc. lost 66.8% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
How much does Zentalis Pharmaceuticals, Inc. owe compared with what it owns?
Zentalis Pharmaceuticals, Inc. owes $0.33 for every $1 it owns (low), lower than 57% of Healthcare companies in United States.
Does Zentalis Pharmaceuticals, Inc. pay a dividend?
No. Zentalis Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.